P1-0189 — Annual report 2010
1.
A process device for coating particles

The existing Wurster chamber has been modified and a new and innovative swirl type of air and particles inside of insert has been achieved.

F.14 Improvements to existing production methods and tools or processes

COBISS.SI-ID: 2807665
2.
Development of new dosage form with quetiapine

In the present invention novel prolonged release pharmaceutical composition is described comprising quetiapine and carrageenan.

F.21 Development of new health/diagnostic methods/procedures

COBISS.SI-ID: 2957937
3.
A. Mrhar, Co-president of the 8th Central European Symposium on Pharmaceutical Technology, Karl-Franzens-University, 16-18 September 2010,Graz,Austria

ZIMMER, Andreas, MRHAR, Aleš, KHINAST, Andreas, ROBLEGG, Eva. [Introduction]. V: 8th Central European Symposium on Pharmaceutical Technology (CESPT), Satellite Symposium: 4th International Graz Congress on Pharmaceutical Engineering, September 16th-18th, Graz, Austria. Abstracts of the 8th Central European Symposium on Pharmaceutical Technology (CESPT), Satellite Symposium: 4th International Graz Congress on Pharmaceutical Engineering, September 16th-18th, Graz, Austria

B.01 Organiser of a scientific meeting

COBISS.SI-ID: 2991217
4.
Gastroresistant pharmaceutical dosage form comprising N-(2-(2-phthalimidoethoxy-acetyl)-L-alanyl-D-glutamic acid (LK-423)

This invention relates to the pharmaceutical dosage forms which enable a controlled and/or a targeted delivery of an active substance to the selected regions of gastrointestinal tract of humans or animals. The pharmaceutical dosage forms preferably comprises the active substance N-(2­(2-phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (designated as LK 423). Methods of treatment of chronic inflammatory diseases of gastrointestinal tract of humans and/or animals by using the pharmaceutical dosage forms of the invention are disclosed.

F.32 International patent

COBISS.SI-ID: 1812337
5.
Development and validation of a patient satisfaction with pharmacy performance questionnaire (PSPP-Q).

A psychometrically valid, multidimensional, self-administered, general questionnaire measuring patient satisfaction with pharmacy performance for outpatients was developed. The questionnaire focuses on issues expressed as important by patients, takes into account services as well as the supporting structure and includes items relevant to an individual pharmacy.

F.22 Improvement to existing health/diagnostic methods/procedures

COBISS.SI-ID: 2806129